Suven Life gets patent from New Zealand for neurological drug

Updated: Tue, Oct 10, 2017
11:59 am
PTI
RELATED NEWS
Monetary Policy announcements exhibit continuity and stability - Expert Ajay Bagga tells Anil Singhvi Monetary Policy announcements exhibit continuity and stability - Expert Ajay Bagga tells Anil Singhvi
RBI Monetary Policy Review: Shaktikanta Das led panel keeps policy rates unchanged RBI Monetary Policy Review: Shaktikanta Das led panel keeps policy rates unchanged
Infosys Chairman Nandan Nilekani on India's Digital Economy I Kotak Institutional Equities highlights details Infosys Chairman Nandan Nilekani on India's Digital Economy I Kotak Institutional Equities highlights details

Drug firm Suven Life Sciences has received a patent from New Zealand for a drug used for treatment of neuro-degenerative diseases.

In a BSE filing today, Suven Life said it has been granted "one product patent from New Zealand corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases".

The patents are valid till 2034, the company added.

Suven Life CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally."

Suven Life Sciences stock was trading 6.08 per cent up at Rs 192 on the BSE in the morning trade.

 

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.